FDA Adverse Event Malfunction Summary report: N

TRUEMETRIX

MDR report key: 8799712 · Received July 17, 2019

Report

Report Number
1000113657-2019-00741
Event Type
Malfunction
Date Received
July 17, 2019
Date of Event
June 21, 2019
Report Date
July 17, 2019
Manufacturer
TRIVIDIA HEALTH, INC.
Product Code
NBW
PMA / PMN Number
K140100
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
MI
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

(B)(4). METER AND TEST STRIPS WERE NOT RETURNED FOR EVALUATION. MOST LIKELY UNDERLYING ROOT CAUSE: MLC-18: USER HAS HIGH GLUCOSE VALUE. TEST STRIPS UDI: (B)(4). MANUFACTURER CONTACTED CUSTOMER IN A FOLLOW-UP CALL TO ENSURE THAT THE REPLACEMENT PRODUCTS RESOLVED THE INITIAL CONCERN - UNABLE TO ESTABLISH CONTACT WITH CUSTOMER AT THIS TIME. PRODUCT NOTIFICATION LETTER SENT TO CONTACT CUSTOMER CARE.

Description of Event or Problem · 1

CONSUMER REPORTED COMPLAINT FOR HIGH BLOOD GLUCOSE TEST RESULTS. THE CUSTOMER IS CONCERNED WITH TEST RESULTS OBTAINED OF 165, 172, 191, 147 AND 151 MG/DL. CUSTOMER WAS ALSO CONCERNED WITH METER TO METER COMPARISON TEST RESULTS OF 161 MG/DL USING METER AND 125 MG/DL USING DOCTOR'S DEVICE. THE CUSTOMER'S EXPECTED FASTING BLOOD GLUCOSE TEST RESULT RANGE IS 100-150 MG/DL. THE CUSTOMER FEELS WELL AND DID NOT REPORT ANY SYMPTOMS. MEDICAL ATTENTION IS NOT REPORTED AS A RESULT OF THE ACTUAL BLOOD GLUCOSE RESULTS. DURING THE CALL, A BACK TO BACK BLOOD TEST WAS PERFORMED BY THE CUSTOMER NON-FASTING AND PRODUCED TEST RESULTS OF 210 MG/DL AND 222 MG/DL USING METER. THE PRODUCT IS STORED ACCORDING TO SPECIFICATION IN THE LIVING ROOM. THE TEST STRIP LOT MANUFACTURER'S EXPIRATION DATE IS 08/21/2020 AND TEST STRIPS WERE OPENED TWO-THREE WEEKS AGO. THE METER MEMORY WAS REVIEWED FOR PREVIOUS TEST RESULT HISTORY: (B)(6).

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
591049 TRUEMETRIX BLOOD GLUCOSE SYSTEM NBW TRIVIDIA HEALTH, INC. TRUEMETRIX MV3163

Patients

Seq Age Sex Outcome Treatment
1 0 YR SECOND THERAPY